Keyword Analysis & Research: remix therapeutics
Keyword Research: People who searched remix therapeutics also searched
Search Results related to remix therapeutics on Search Engine
-
Home - Remix Therapeutics
https://www.remixtx.com/
WEBFeb 1, 2024 · Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins.
DA: 88 PA: 92 MOZ Rank: 58
-
About Us - Remix Therapeutics
https://www.remixtx.com/about/
WEBOur breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
DA: 78 PA: 65 MOZ Rank: 97
-
Our Science - Remix Therapeutics
https://www.remixtx.com/science/
WEBDetermined to deliver novel and impactful treatments, Remix™ sets about advancing our breakthrough discoveries into innovative and relevant medicines. Our first act is tackling previously undrugged oncogenic transcription factors to eradicate certain solid tumors and hematological malignancies.
DA: 78 PA: 2 MOZ Rank: 57
-
Remix Therapeutics™ Closes $60 Million Financing to Advance …
https://www.remixtx.com/remix-therapeutics-closes-60-million-financing-to-advance-rem-422-pipeline-of-small-molecule-therapies-designed-to-reprogram-rna-processing-to-treat-disease/
WEBCambridge, Mass. (January 3, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group.
DA: 67 PA: 90 MOZ Rank: 22
-
Remix Therapeutics™ Enters Collaboration with Roche for the …
https://www.remixtx.com/remix-therapeutics-enters-collaboration-with-roche-for-the-discovery-and-development-of-small-molecule-therapeutics-modulating-rna-processing/
WEBWatertown, Mass. (January 3, 2024) – Remix Therapeutics (Remix), a clinical stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced a collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and …
DA: 26 PA: 58 MOZ Rank: 20
-
Remix Therapeutics Enters Collaboration with Roche for the …
https://www.prnewswire.com/news-releases/remix-therapeutics-enters-collaboration-with-roche-for-the-discovery-and-development-of-small-molecule-therapeutics-modulating-rna-processing-302024970.html
WEBJan 3, 2024 · Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster ™ technology platform...
DA: 11 PA: 56 MOZ Rank: 83
-
First small-molecule drug targeting RNA gains momentum
https://www.nature.com/articles/s41587-020-00788-1.pdf
WEBRNA-targeting drugs. Remix Therapeutics, the latest such contender to emerge, disclosed an $81 million series A round on 8 December and unveiled plans to develop oral drugs that target and...
DA: 83 PA: 35 MOZ Rank: 65
-
Remix Therapeutics Launches with $81 Million Financing to …
https://www.remixtx.com/remix-therapeutics-launches-with-81-million-financing-to-develop-small-molecule-therapies-designed-to-reprogram-rna-processing/
WEBDec 8, 2020 · Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression.
DA: 41 PA: 12 MOZ Rank: 71
-
Remix Therapeutics Enters Collaboration with Janssen to …
https://www.remixtx.com/remix-therapeutics-enters-collaboration-with-janssen-to-advance-small-molecule-therapeutics-using-remaster-drug-discovery-platform-to-modulate-rna-processing/
WEBCambridge, Mass. (February 17, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced a strategic collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson …
DA: 63 PA: 76 MOZ Rank: 65
-
Remix Therapeutics Launches with $81 Million Financing to …
https://www.prnewswire.com/news-releases/remix-therapeutics-launches-with-81-million-financing-to-develop-small-molecule-therapies-designed-to-reprogram-rna-processing-301187843.html
WEBDec 8, 2020 · Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology...
DA: 75 PA: 24 MOZ Rank: 92
